骨髓增殖性肿瘤血栓事件的治疗现状

刘苗苗; 郭涛

doi:10.13201/j.issn.1004-2806.2021.01.003

骨髓增殖性肿瘤血栓事件的治疗现状

刘苗苗,
郭涛^,

- 华中科技大学同济医学院附属协和医院血液内科(武汉, 430022)
基金项目:
国家自然科学基金面上项目(No:81974008)

详细信息

作者简介:
郭涛,华中科技大学同济医学院附属协和医院血液科主任医师、博士生导师。担任中国医师协会血液科医师分会委员,海峡两岸医药卫生交流协会血液病学专业委员会副主任委员,武汉血液学会主任委员,中国研究型医院协会生物治疗学组常务委员。《临床血液学杂志》,《血栓与止血学杂志》,《国际输血及血液学杂志》及《临床急诊杂志》编委。

通讯作者: 郭涛,E-mail:guotao1968@163.com

中图分类号: R551.3

收稿日期: 2020-12-01

Current status of the treatment of thrombotic events in myeloproliferative neoplasm

LIU Miaomiao,
GUO Tao^,

More Information

Corresponding author: GUO Tao, E-mail: guotao1968@163.com

Received Date: 01 December 2020

摘要

摘要: 骨髓增殖性肿瘤（myeloproliferative neoplasm,MPN）是一组克隆性造血干细胞疾病,以红细胞,巨核细胞或粒细胞系中的一个或多个髓细胞系过度增殖为特征;临床表现为一种或多种血细胞增生,伴肝脾或淋巴结肿大,有白血病转化风险。根据2016年WHO淋巴/造血组织肿瘤分类,经典费城染色体阴性MPN包括真性红细胞增多症（polycythemia vera,PV）,原发性血小板增多症（essential thrombocythemia,ET）和原发性骨髓纤维化（primary myelofibrosis,PMF）。血栓和出血事件是MPN患者重要的发病和死亡原因,降低其发生率成为MPN患者治疗的主要目标。本文就MPN患者血栓形成机制,风险分层和相应防治策略展开叙述。
- 骨髓增殖性肿瘤 /
- 血栓并发症 /
- 治疗 /
- 风险分层
- myeloproliferative neoplasm /
- thrombotic complications /
- treatment /
- risk stratification

HTML全文

参考文献(34)

[1]	Kaifie A,Kirschner M,Wolf D,et al.Bleeding,thrombosis,and anticoagulation in myeloproliferative neoplasms(MPN):analysis from the German SAL-MPN-registry[J].J Hematol Oncol,2016,9:18.
[2]	De Stefano V,Vannucchi AM,Ruggeri M,et al.Splanchnic vein thrombosis in myeloproliferative neoplasms:risk factors for recurrences in a cohort of 181 patients[J].Blood Cancer J,2016,6(11):e493.
[3]	Kc D,Falchi L,Verstovsek S.The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis:a review[J].Ann Hematol,2017,96(10):1595-1604.
[4]	Barbui T,Carobbio A,Cervantes F,et al.Thrombosis in primary myelofibrosis:incidence and risk factors[J].Blood,2010,115(4):778-782.
[5]	Tevet M,Ionescu R,Dragan C,et al.Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders[J].Maedica(Bucur),2015,10(1):27-32.
[6]	Cervantes F,Alvarez-Larrán A,Arellano-Rodrigo E,et al.Frequency and risk factors for thrombosis in idiopathic myelofibrosis:analysis in a series of 155 patients from a single institution[J].Leukemia,2006,20(1):55-60.
[7]	De Grandis M,Cambot M,Wautier MP,et al.JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway[J].Blood,2013,121(4):658-665.
[8]	Edelmann B,Gupta N,Schnoeder T M,et al.JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation[J].J Clin Invest,2018,128(10):4359-4371.
[9]	Wolach O,Sellar RS,Martinod K,et al.Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms[J].Sci Transl Med,2018,10(436):eaan8292
[10]	Fuchs TA,Brill A,Duerschmied D,et al.Extracellular DNA traps promote thrombosis[J].Proc Natl Acad Sci U S A,2010,107(36):15880-15885.
[11]	Barbui T,Tefferi A,Vannucchi AM,et al.Philadelphia chromosome-negative classical myeloproliferative neoplasms:revised management recommendations from European LeukemiaNet[J].Leukemia,2018,32(5):1057-1069.
[12]	Landolfi R,Marchioli R,Kutti J,et al.Efficacy and safety of low-dose aspirin in polycythemia vera[J].N Engl J Med,2004,350(2):114-124.
[13]	Marchioli R,Finazzi G,Specchia G,et al.Cardiovascular events and intensity of treatment in polycythemia vera[J].N Engl J Med,2013,368(1):22-33.
[14]	Tefferi A,Vannucchi AM,Barbui T.Polycythemia vera treatment algorithm 2018[J].Blood Cancer J,2018,8(1):3.
[15]	Tefferi A,Vannucchi AM,Barbui T.Essential thrombocythemia treatment algorithm 2018[J].Blood Cancer J,2018,8(1):2.
[16]	Awada H,Voso MT,Guglielmelli P,et al.Essential Thrombocythemia and Acquired von Willebrand Syndrome:The Shadowlands between Thrombosis and Bleeding[J].Cancers,2020,12(7):1746.
[17]	Barbui T,Barosi G,Birgegard G,et al.Philadelphia-negative classical myeloproliferative neoplasms:critical concepts and management recommendations from European LeukemiaNet[J].J Clin Oncol,2011,29(6):761-770.
[18]	Pascale S,Petrucci G,Dragani A,et al.Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target[J].Blood,2012,119(15):3595-3603.
[19]	Alvarez-Larrán A,Pereira A,Guglielmelli P,et al.Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation[J].Haematologica,2016,101(8):926-931.
[20]	Tefferi A,Barbui T.Polycythemia vera and essential thrombocythemia:2019 update on diagnosis,risk-stratification and management[J].Am J Hematol,2019,94(1):133-143.
[21]	Vannucchi AM,Kiladjian JJ,Griesshammer M,et al.Ruxolitinib versus standard therapy for the treatment of polycythemia vera[J].N Engl J Med,2015,372(5):426-435.
[22]	Gisslinger H,Klade C,Georgiev P,et al.Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera(PROUD-PV and CONTINUATION-PV):a randomised,non-inferiority,phase 3 trial and its extension study[J].Lancet Haematol,2020,7(3):e196-e208.
[23]	Chifotides HT,Bose P,Verstovsek S.Givinostat:an emerging treatment for polycythemia vera[J].Expert Opin Investig Drugs,2020,29(6):525-536.
[24]	Finazzi G,Vannucchi AM,Barbui T.Prefibrotic myelofibrosis:treatment algorithm 2018[J].Blood Cancer J,2018,8(11):104.
[25]	Fedratinib Becomes New Option in Myelofibrosis[J].Cancer Discov,2019,9(10):1332.
[26]	Verstovsek S,Gotlib J,Mesa RA,et al.Long-term survival in patients treated with ruxolitinib for myelofibrosis:COMFORT-I and-II pooled analyses[J].J Hematol Oncol,2017,10(1):156.
[27]	Kearon C,Akl EA,Comerota AJ,et al.Antithrombotic therapy for VTE disease:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e419S-e496S.
[28]	Finazzi G,De Stefano V,Barbui T.Splanchnic vein thrombosis in myeloproliferative neoplasms:treatment algorithm 2018[J].Blood Cancer J,2018,8(7):64.
[29]	De Stefano V,Carobbio A,Di Lazzaro V,et al.Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms[J].Blood Cancer J,2018,8(3):25.
[30]	Lansberg MG,O'donnell MJ,Khatri P,et al.Antithrombotic and thrombolytic therapy for ischemic stroke:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e601S-e636S.
[31]	Amarenco P.Transient Ischemic Attack[J].N Engl J Med,2020,382(20):1933-1941.
[32]	Prasad K,Siemieniuk R,Hao Q,et al.Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke:a clinical practice guideline[J].BMJ,2018,363:k5130.
[33]	Fukuda K,Yokoi Y.Endovascular approach for acute limb ischemia without thrombolytic therapy[J].Ther Adv Cardiovasc Dis,2020,14:1753944720924575.
[34]	Cerquozzi S,Barraco D,Lasho T,et al.Risk factors for arterial versus venous thrombosis in polycythemia vera:a single center experience in 587 patients[J].Blood Cancer J,2017,7(12):662.